5-HT2A receptor - how psychedelics activate brain plasticity
Receptor 5-HT2A — co to, co mowia badania i status prawny w Polsce. u Bucha.
Every classic psychedelic - psilocybin, LSD, DMT, mescaline - has one common entry point into the brain: the 5-HT2A serotonin receptor. This is not a coincidence, but a fundamental pharmacological property of this class of substances. Understanding what this receptor is, where it is located, and what happens after its activation is key to understanding both the therapeutic potential of psychedelics and their subjective effects. This article explains the neuroscience of 5-HT2A in an accessible way, but without oversimplifications that miss the truth.
KEY INFORMATION
• The blockade of the 5-HT2A receptor by ketanserin completely abolishes the effects of psilocybin - evidence that 5-HT2A is the gateway for classic psychedelics (Vollenweider et al., Neuropsychopharmacology, 1998).
• Psychedelics activate TrkB (neurotrophin receptor) independently of BDNF, which explains the rapid growth of dendrites and synaptic spines after a single dose (Molnár et al., Nature, 2023).
• The destabilization of the DMN (default mode network) by 5-HT2A explains both subjective effects and the therapeutic reduction of rumination.
• „Biased agonism” at 5-HT2A - the possibility of separating neuroplastic effects from psychedelic ones - is an active area of pharmacological research.
Czym jest receptor 5-HT2A - budowa i lokalizacja
The 5-HT2A receptor (5-hydroxytryptamine receptor 2A) belongs to the family of metabotropic receptors coupled with G proteins, specifically with the Gq/11 subtype. Its activation triggers the phospholipase C (PLC) pathway, leading to the production of inositol trisphosphate (IP3) and diacylglycerol (DAG) - secondary messengers that activate protein kinase C and release calcium from the endoplasmic reticulum (Nichols, Pharmacological Reviews, 2016).
The localization of 5-HT2A in the brain is uneven and functionally significant. The highest density is found in layer V of the prefrontal cortex (PFC), hippocampus, sensory and visual cortex, and certain thalamic nuclei. The prefrontal cortex is particularly important: it integrates information, moderates attention, and creates predictive models of reality. When 5-HT2A in the PFC is strongly activated by a psychedelic, this hierarchy of predictions is temporarily disrupted - which directly translates into altered perception and thinking.
The 5-HT2A receptor also exhibits "constitutive activity" - a baseline activity even in the absence of a ligand. This means that its modulation is a dynamic process, not a binary switch. In patients with depression, the density of 5-HT2A in the prefrontal cortex is elevated - which is interpreted as compensatory hypersensitization in the context of serotonin deficiency and corresponds to the therapeutic mechanism of both SSRIs and psychedelics.
Evidence for the key role of 5-HT2A: the experiment with ketanserin
The most important evidence for the central role of 5-HT2A in the action of psychedelics comes from studies blocking this receptor. Ketanserin is a selective 5-HT2A antagonist clinically used as an antihypertensive drug. In an early study by Vollenweider and colleagues, administering ketanserin before psilocybin completely abolished the subjective psychedelic effects in healthy volunteers (Vollenweider et al., Neuropsychopharmacology, 1998).
This result - replicated multiple times for different substances (LSD, DMT, mescaline) - provides strong causal evidence. It's not just about correlation: without 5-HT2A, there are no psychedelic effects. Activation of 5-HT1A or 5-HT2C (other serotonin subtypes) does not reproduce the effect. This pharmacological "fingerprinting" has clearly separated the mechanism of classical psychedelics from other psychoactive substances and built a rational basis for therapeutic research.
| Substance | Action on 5-HT2A | Psychedelic effect | Notes |
|---|---|---|---|
| Psilocybin (active metabolite of psilocybin) | Full agonist | Yes | Short duration of action (4-6 h) |
| LSD | Full agonist | Yes | Long duration of action (8-12 h) |
| DMT | Full agonist | Yes | Very short duration (20-30 min) |
| Ketanserin | Antagonist | Nie - blokuje psychodeliki | Clinically used as an antihypertensive drug |
| Tabernanthalog | Biased agonist | None (studies on mice) | Psychoplastogen without hallucinogenicity - studies pending. |
We have noticed that in popular science discourse, two distinct concepts are often mixed: "serotonergic" and "acting through 5-HT2A". Many drugs modify serotonin (SSRIs, triptans, anti-migraine medications), but none of them are psychedelic - because they are not 5-HT2A agonists. SSRIs paradoxically reduce the density and sensitivity of 5-HT2A after prolonged use (desensitization), which may explain why SSRIs weaken the effects of psilocybin when used concurrently.
From 5-HT2A to neuroplasticity: the discovery of the TrkB pathway
For years, it was assumed that the increase in neuroplasticity after psychedelics is an indirect effect of 5-HT2A activation: through increased glutamate release in the prefrontal cortex, stimulation of AMPA receptors, and secondary increase of BDNF (brain-derived neurotrophic factor). This explanation was mechanically correct but incomplete.
The breakthrough came with an article in Nature from 2023 (Molnár et al., Nature, 2023). Researchers have shown that psychoplastogens (psilocybin, ketamine, LSD, MDMA, and several others) directly activate the TrkB receptor - a neurotrophin receptor normally activated by BDNF - through an allosteric binding mechanism to the transmembrane domain, completely different from the BDNF binding site. This pathway is independent of 5-HT2A and operates in parallel.
Consequence: psychoplastogens activate two separate neuroplasticity pathways simultaneously. First, through 5-HT2A, they destabilize existing networks and open a "window of critical plasticity". Second, through TrkB, they directly stimulate dendritic growth and the formation of synaptic spines. This duality may explain why the neuroplastic effects are faster and more lasting than with mere stimulation of BDNF or SSRIs.
Biased agonism - can neuroplasticity be separated from psychedelic effects?
This is one of the hottest questions in neuropsychopharmacology in recent years. The concept of "biased agonism" at 5-HT2A refers to the ability to selectively activate only certain signaling pathways through the receptor - for example, the neuroplasticity pathway without the pathway responsible for hallucinogenic perception.
Initial evidence for the concept comes from studies on rodents. Tabernanthalog, a synthetic analog of ibogaine, exhibits neuroplastic effects (increased dendritic spine density) without hallucinogenic behavioral effects in mouse tests (Cameron et al., Nature, 2021). If this pharmacological profile were confirmed in humans, it would pave the way for "psychoplastogens without psychosis" - substances with the therapeutic potential of psychedelics, but without the difficulties arising from the psychedelic experience itself.
From our experience in tracking the scientific literature: biased agonism at 5-HT2A is a fascinating concept, but still deeply preclinical. The gap between results in rodents and human pharmacology is exceptionally wide in this field - subjective experiences, which are key to the therapeutic effects of psychedelics, do not exist at all in rodent models. Caution in extrapolation is particularly warranted here.
5-HT2A in the context of other diseases - depression, schizophrenia, migraine
The 5-HT2A receptor is not only important for understanding psychedelics - it plays a central role in the neurobiology of several significant clinical conditions. In schizophrenia: atypical second-generation antipsychotic drugs (olanzapine, quetiapine, risperidone) act as antagonists of 5-HT2A. Blocking this receptor reduces excessive activity in the prefrontal cortex and alleviates both positive and negative symptoms of schizophrenia. This explains why psychedelics (5-HT2A agonists) are absolutely contraindicated in individuals predisposed to psychosis - they can trigger a psychotic episode by excessively stimulating the same receptor that antipsychotic medications block.
In depression: the density and sensitivity of 5-HT2A increase with chronic stress and depression as compensation for serotonin deficiency (upregulation of receptors). Paradoxically, SSRIs - drugs that increase serotonin levels - cause downregulation of 5-HT2A over time (decreased receptor density), which may be one of the mechanisms of their therapeutic action. Psychedelics act in the opposite way: they intensely activate 5-HT2A at once, causing deep destabilization and subsequent recalibration of neural networks - an effect different from the subtle, gradual regulation by SSRIs.
In migraine: agonism of 5-HT1B/1D (triptans) acts therapeutically by constricting cerebral blood vessels, but antagonism of 5-HT2A by methysergide (a historical preventive migraine medication) has also been effective - indicating the role of 5-HT2A in the pathophysiology of migraine. An interesting clinical observation: microdosing with psilocybin (sub-perceptual doses of 0.1-0.3 mg) is reported anecdotally to reduce the frequency of migraine attacks - but this requires formal clinical verification, which is currently lacking.
Understanding the role of 5-HT2A in these conditions shows that this receptor is a "node" connecting many seemingly distant areas of neuropsychiatry. Modulating this one receptor - depending on the direction (agonism vs. antagonism), dose, and context - can lead to radically different clinical effects.
It is also worth mentioning the role of 5-HT2A in sleep regulation. This receptor is highly active during REM sleep and modulates sleep architecture. 5-HT2A antagonists (e.g., trazodone, mirtazapine) improve deep sleep quality and prolong the slow-wave phase - which is one of the mechanisms of their calming effect. 5-HT2A agonists may suppress REM, which explains why psychedelics taken in the evening can disrupt sleep - and why clinical protocols recommend sessions in the morning or afternoon rather than in the evening. This diurnal sensitivity of 5-HT2A to activation provides another argument that the context and timing of using substances acting on this receptor have clinical significance, not just symbolic.
Frequently Asked Questions
What is the 5-HT2A receptor and where is it located?
The 5-HT2A receptor is a metabotropic serotonin receptor coupled with the Gq/11 protein. It has the highest density in layer V of the prefrontal cortex, the hippocampus, and the sensory cortex. It regulates glutamatergic activity and modulates the state of excitation of cortical networks responsible for perception and information integration (Nichols, Pharmacological Reviews, 2016).
Why is 5-HT2A crucial for the action of psychedelics?
Blockade of 5-HT2A by ketanserin completely abolishes the subjective effects of psilocybin and LSD. Activation of 5-HT2A by agonists (psilocin, LSD, DMT) triggers a signaling cascade that destabilizes hierarchical cortical networks and enhances neuroplasticity (Vollenweider et al., 1998).
How does activation of 5-HT2A lead to neuroplasticity?
Through two parallel pathways: via the glutamate cascade (AMPA, BDNF) and through direct allosteric binding to the TrkB receptor independent of BDNF. This second mechanism was discovered in 2023 and explains the rapid growth of dendrites after a single dose (Molnár et al., Nature, 2023).
Are all substances acting on 5-HT2A psychedelic?
No. 5-HT2A antagonists (ketanserin, atypical antipsychotic drugs like olanzapine) block the receptor without psychedelic effects. Full agonists induce psychedelic effects, while "biased agonists" may selectively activate neuroplastic pathways - this is an active area of pharmacological research.
What are non-psychedelic psychoplastogens?
These are substances that induce neuroplasticity (through TrkB or related pathways) without dissociative effects. Tabernanthalog has shown such a profile in rodents (Cameron et al., Nature, 2021). None have yet entered phase 3 clinical trials. Ketamine (through NMDA, not 5-HT2A) and esketamine (Spravato) are closest to clinical application as psychoplastogens without classical psychedelics.
This article is for informational and educational purposes and does not constitute legal advice. The legal status described in the article is valid as of the publication date - regulations regarding cannabis may change. Consult a lawyer or current legal acts before making decisions.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
